The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review

Hector Meijide; Savino Sciascia; Giovanni Sanna; Munther A Khamashta; Maria Laura Bertolaccini

doi:10.1016/j.autrev.2012.08.002

The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review

Hector Meijide, Savino Sciascia, Giovanni Sanna, Munther A Khamashta, Maria Laura Bertolaccini

Women & Children's Health

Research output: Contribution to journal › Review article › peer-review

70 Citations (Scopus)

Abstract

The antiphospholipid syndrome (APS) is diagnosed in patients with thromboembolic events and/or pregnancy loss in the presence of persistent laboratory evidence for antiphospholipid antibodies (aPL). Diagnostic tests for the detection of antiphospholipid antibodies include laboratory assays that detect anticardiolipin antibodies, lupus anticoagulants, and anti-β(2)-glycoprotein I antibodies. Most studies on aPL have mainly focused on the estimation of the IgG and IgM isotypes, with only a few studies reporting on the pathogenic significance of IgA aPL. In this review we aimed to summarize and analyze the evidence published in the literature on the prevalence and the clinical significance of IgA aPL.

Original language	English
Article number	N/A
Pages (from-to)	421-425
Number of pages	5
Journal	AUTOIMMUNITY REVIEWS
Volume	12
Issue number	3
DOIs	https://doi.org/10.1016/j.autrev.2012.08.002
Publication status	Published - Jan 2013

Keywords

Antibodies, Anticardiolipin
Antiphospholipid Syndrome
Humans
Immunoglobulin A
Seroepidemiologic Studies
beta 2-Glycoprotein I

Access to Document

10.1016/j.autrev.2012.08.002

Cite this

@article{695f3c3ec0834369b0e065e2a26a60af,

title = "The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review",

abstract = "The antiphospholipid syndrome (APS) is diagnosed in patients with thromboembolic events and/or pregnancy loss in the presence of persistent laboratory evidence for antiphospholipid antibodies (aPL). Diagnostic tests for the detection of antiphospholipid antibodies include laboratory assays that detect anticardiolipin antibodies, lupus anticoagulants, and anti-β(2)-glycoprotein I antibodies. Most studies on aPL have mainly focused on the estimation of the IgG and IgM isotypes, with only a few studies reporting on the pathogenic significance of IgA aPL. In this review we aimed to summarize and analyze the evidence published in the literature on the prevalence and the clinical significance of IgA aPL.",

keywords = "Antibodies, Anticardiolipin, Antiphospholipid Syndrome, Humans, Immunoglobulin A, Seroepidemiologic Studies, beta 2-Glycoprotein I",

author = "Hector Meijide and Savino Sciascia and Giovanni Sanna and Khamashta, {Munther A} and Bertolaccini, {Maria Laura}",

year = "2013",

month = jan,

doi = "10.1016/j.autrev.2012.08.002",

language = "English",

volume = "12",

pages = "421--425",

journal = "AUTOIMMUNITY REVIEWS",

issn = "1568-9972",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies

T2 - a systematic review

AU - Meijide, Hector

AU - Sciascia, Savino

AU - Sanna, Giovanni

AU - Khamashta, Munther A

AU - Bertolaccini, Maria Laura

PY - 2013/1

Y1 - 2013/1

N2 - The antiphospholipid syndrome (APS) is diagnosed in patients with thromboembolic events and/or pregnancy loss in the presence of persistent laboratory evidence for antiphospholipid antibodies (aPL). Diagnostic tests for the detection of antiphospholipid antibodies include laboratory assays that detect anticardiolipin antibodies, lupus anticoagulants, and anti-β(2)-glycoprotein I antibodies. Most studies on aPL have mainly focused on the estimation of the IgG and IgM isotypes, with only a few studies reporting on the pathogenic significance of IgA aPL. In this review we aimed to summarize and analyze the evidence published in the literature on the prevalence and the clinical significance of IgA aPL.

AB - The antiphospholipid syndrome (APS) is diagnosed in patients with thromboembolic events and/or pregnancy loss in the presence of persistent laboratory evidence for antiphospholipid antibodies (aPL). Diagnostic tests for the detection of antiphospholipid antibodies include laboratory assays that detect anticardiolipin antibodies, lupus anticoagulants, and anti-β(2)-glycoprotein I antibodies. Most studies on aPL have mainly focused on the estimation of the IgG and IgM isotypes, with only a few studies reporting on the pathogenic significance of IgA aPL. In this review we aimed to summarize and analyze the evidence published in the literature on the prevalence and the clinical significance of IgA aPL.

KW - Antibodies, Anticardiolipin

KW - Antiphospholipid Syndrome

KW - Humans

KW - Immunoglobulin A

KW - Seroepidemiologic Studies

KW - beta 2-Glycoprotein I

U2 - 10.1016/j.autrev.2012.08.002

DO - 10.1016/j.autrev.2012.08.002

M3 - Review article

C2 - 22951216

SN - 1568-9972

VL - 12

SP - 421

EP - 425

JO - AUTOIMMUNITY REVIEWS

JF - AUTOIMMUNITY REVIEWS

IS - 3

M1 - N/A

ER -

The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review

Abstract

Keywords

Access to Document

Fingerprint

Cite this